

Prepared in accordance with section 15 of the Broader Public Sector Accountability Act, 2010 (BPSAA)

TO: The Board of Trillium Health Partners, (the “Board”)
FROM: Karli Farrow
President & Chief Executive Officer
Trillium Health Partners
Date: June 5th, 2025
RE: April 1, 2024 to March 31, 2025 (“the Applicable Period”)

On behalf of Trillium Health Partners (the Hospital) I attest, with best efforts, to:

- the completion and accuracy of reports required of the Hospital pursuant to section 6 of the BPSAA on the use of consultants;
- the Hospital’s compliance with the prohibition in section 4 of the BPSAA on engaging lobbyist services using public funds;
- the Hospital’s compliance with any applicable expense claims directives issued under section 10 of the BPSAA by the Management Board of Cabinet;
- the Hospital’s compliance with any applicable perquisite directives issued under section 11.1 of the BPSAA by the Management Board of Cabinet; and
- the Hospital’s compliance with any applicable procurement directives issued under section 12 of the BPSAA by the Management Board of Cabinet,
- the Hospital’s compliance with any applicable directives issued under section 13 of the BPSAA by the Management Board of Cabinet on the preparation and publication of business plans and other business or financial documents, during the Applicable Period.

In making this attestation, I have exercised care and diligence that would reasonably be expected of a Hospital President and Chief Executive Officer in these circumstances, including making due inquiries of Hospital staff that have knowledge of these matters including THP’s Chief Financial Officer, Senior Leadership, Controller, and Legal Counsel.

I further certify that any material exceptions to this attestation are documented in the attached Schedule A.

Dated at Mississauga, Ontario this June 5, 2025.



Karli Farrow
President and Chief Executive Officer

I certify that this attestation has been approved by Trillium Health Partners’ Board of Directors on June 5, 2025.



Joan Mohammed
Board Chair

SCHEDULE A to Attestation

1. Exceptions to the completion and accuracy of reports required in section 6 of the BPSAA on the use of consultants;

No Known Material Exceptions

Please see the Hospital Reporting on Consultant Use.

2. Exceptions to the Hospital's compliance with the prohibition in section 4 of the BPSAA on engaging lobbyist services using public funds;

No Known Material Exceptions

3. Exceptions to the Hospital's compliance with the expense claims directive issued under section 10 of the BPSAA by the Management Board of Cabinet;

No Known Material Exceptions

4. Exceptions to the Hospital's compliance with the perquisites directives issued under section 11.1. of the BPSAA by the Management Board of Cabinet;

No Known Material Exceptions

5. Exceptions to the Hospital's compliance with the procurement directive issued under section 12 of the BPSAA by the Management Board of Cabinet,

Please see:

- Mohawk Medbuy Corporation Letter in connection with the Broader Public Sector Procurement Directive and applicable trade agreements
 - Attestations from other shared services and procurement organizations
6. Exceptions to the Hospital's compliance with the directives issued under section 13 of the BPSAA by the Management Board of Cabinet on the preparation and publication of business plans and other business or financial documents.

- No known exceptions

March 31, 2025

Karli Farrow
President & CEO
Trillium Health Partners
2200 Eglinton Avenue West,
Mississauga, ON L5M 2N1

Dear Ms. Farrow:

Compliance with the Broader Public Sector Procurement Directive and applicable trade agreements

We provide this letter in connection with compliance of Trillium Health Partners' ("you", "your" or "Hospital") procurement contracts administered and completed by **Mohawk Medbuy Corporation ("MMC" or "us")** from **April 1, 2024 to March 31, 2025 ("the Applicable Period")** with the Broader Public Sector Procurement Directive issued under Section 12 of the *Broader Public Sector Accountability Act* by the Management Board of Cabinet and the applicable trade agreements (i.e., Canada Free Trade Agreement and Canada-European Union Comprehensive Economic and Trade Agreement), all jointly referred to hereinafter as the "**Procurement Directive**".

For procurements (including redevelopment contracts) partly managed by MMC during the Applicable Period, this attestation applies only to the portion of the work performed by us. For contracts that you participated in, completed by other shared services and procurement organizations ("**Other SSO**"), the attestations of the Other SSOs relating to such contracts are attached at Appendix 2.

In making this attestation, we have exercised care and diligence that would reasonably be expected of a **Senior Vice President, Strategic Sourcing**, in these circumstances, including reviewing our internal compliance framework, making due inquiries of staff that have knowledge of these matters, internal attestations received from our sourcing management staff, and the results of an internal review conducted by us of a sample drawn from all contracts completed by MMC during the Applicable Period ("**the Review**").

Procurement Directive compliance:

- We have completed procurement contracts for goods and services, including consulting services, on your behalf in accordance with the Procurement Directive to the extent of its applicability to our work, and will be providing you a list of all our findings resulting from the Review. The scope of the Review and material exceptions to the Procurement Directive noted are comprised in the attached Appendix 1.

Policy compliance:

- We acknowledge that we are responsible for ensuring that your contracts are executed in compliance with the Procurement Directive and your specific policies and have designed and implemented an internal control framework to prevent and detect deviations therefrom.
- We have taken steps to retain all material documentation, information, and communication related to the procurement processes, in a recoverable format, in accordance with the Procurement Directive and your policies.

Communications from Government authorities:

- There have been no communications from the Ministry of Finance or any other regulatory or government agency concerning non-compliance, or potential deficiencies in compliance, with the Procurement Directive or any other related legislated directive or policy.

Potential legal disputes:


- In relation to the procurements completed by us on your behalf, we've informed your Chief Financial Officer of any significant bid disputes or other matters which could potentially expose you to legal risk or contingent liabilities immediately upon learning of the same. All of them were satisfactorily resolved during the Applicable Period.


The following listings are provided in the attached appendices:

1. Material exceptions – Appendix 1; and
2. Attestation(s) from other agencies - Appendix 2

Yours truly,


Marc Lemaire
Senior Vice President
Strategic Sourcing


Kyle Watts (May 15, 2025 12:36 EDT)
Kyle Watts
Vice President,
Finance & Integration


Anisha Sinha (May 15, 2025 13:56 EDT)
Anisha Sinha
Vice President, Account
Management & Integration

Appendix 1

Material Exceptions

Note: Terms used in this Appendix are either defined herein or in the accompanying attestation letter.

Scope - Defined

We conducted an internal review (“the Review”) of a sample comprising 50 contracts drawn from all the contracts managed and completed by us during the Applicable Period. The contracts comprised in the sample were selected based on their spend value and complexity. Results of the Review are provided in Part-A below. Our findings, conclusions and comments are based solely on our review of this sample.

Scope - Exclusion

The scope of the Review excluded testing compliance with the following Mandatory Requirements (MR), since the accountability of all the aspects thereof do not fully vest in MMC:

MR #1 – Hospital Segregation of Duties:

- Organizations must segregate at least three of the five functional procurement roles: Requisition, Budgeting, Commitment, Receipt and Payment. Responsibilities for these roles must lie with different departments or, at a minimum, with different individuals. Where it is not feasible to segregate these roles, i.e., for smaller organizations, adequate compensating controls approved by an external auditor must be put in place.

MR #2 – Establishment of the Approval Authority:

- Organizations must establish an approval authority schedule (AAS) for procurement of goods and non-consulting services. The AAS must be approved by the Board of Directors of the organization or its equivalent prior to commencement of procurement.

MR #22 – Contract Management:

- Payments must be made in accordance with provisions of the contract. All invoices must contain detailed information sufficient to warrant payment. Any overpayments must be recovered in a timely manner.
- Establish expense claim and reimbursement rules compliant with the Broader Public Sector Expenses Directive and ensure all expenses are claimed and reimbursed in accordance with these rules.
- Ensure that expenses are claimed and reimbursed only where the contract explicitly provides for reimbursement of expenses.

Appendix 1

Material Exceptions

General Observations

In a few cases, the Review found some documents had not been retained by MMC after completion of the procurement process. Corroborating evidence was however found elsewhere to support compliance of such contracts with the Procurement Directive.

Procurements conducted in the following circumstances were so conducted for compelling business reasons and have not been individually listed herein:

1. In terms of the evolving Provincial agenda, several shared services organizations in Ontario are working collaboratively to consolidate contracts for certain high-value products. MMC too has aligned the end date of some of its agreements with the expected start dates of these consolidated contracts, resulting in exceptions to MR #18 (term of agreement modifications) for such contracts identified during the Review. Such harmonization has generally preserved the current pricing and supply continuity to the participating hospitals (including you).
2. The Canadian Free Trade Agreement requires public posting of award notice for Limited Tender procurements. In certain cases, including the foregoing, such posting was delayed beyond the prescribed time periods.



Appendix 1
Material Exceptions

Exceptions Noted:

Part A: Following material exceptions were identified as a result of the Review of the sample referred to above:

Contract ID	Contract Description	Procurement Type	Vendor Name	Term + Option (years)	Estimated Non-Compliance	MR #	Comments
210817	Linac Service Agreement	Open Competitive-Piggyback	Varian Medical System	4 years	\$380,000	18, 21	Term of piggyback contract has been extended beyond the term of the prime agreement. Proper approval for the non-competitive piggyback extension has not been obtained.

Appendix 1

Material Exceptions

Part-B: To maximize value for money and for the hospital's benefit, purchases under the following contracts commenced after all the terms and conditions of the contract had been finalized but before it was formally signed and/or terms and conditions of the expiring contracts were maintained while procurement process was being conducted for the new contract (MR#15: Executing the contract). The delayed timing, in some cases, were a result of protracted negotiations to get best value, short notice of additional funding/planning issues and competing priorities with available resources while ensuring patient care.

Contracts with significant gaps between first purchase and formal execution are provided in the table below:

Contract ID	Contract Description	Vendor Name	Contract Completion Year (Actual/Estimated)	Estimated Current Year Spend Until Contract Signature
212129	Neuro Product Supply Agreement	Multiple vendors	FY24/25	\$936,000
211952	Endoscopic Vessel Harvesting Product Supply Agreement	Getinge Canada Limited	FY24/25	\$906,000
212268	Prenatal Screening Analyzer Consumables & Service Agreement	Revvity Health Sciences Canada	FY24/25	\$827,000
215000	Surgical Gloves Product Supply Agreement	Ansell Canada	FY24/25	\$386,000
156231	Trauma - Foot & Ankle Product Supply Agreement	Johnson & Johnson	FY24/25	\$242,000

Abbreviations:

MR#18: Term of Agreement Modifications

MR#21: Non-Competitive Procurement



March 25, 2025

Attestation to the BPSAA Supply Chain Secretariat BPS Directive and Canada Free Trade Agreement (CFTA) Compliance

Dear Member,

Mohawk Medbuy Corporation fully understands and abides by the Ontario Ministry of Finance Broader Public Sector Supply Chain Directives and the Canada Free Trade Agreement (CFTA) meant to ensure that publicly funded goods and services are acquired by BPS organizations through a process that is open, fair, and transparent.

On behalf of Mohawk Medbuy Corporation, we attest that all contracting services performed on the Members' behalf for the applicable period of April 1, 2024 – March 31, 2025, are in compliance with the Broader Public Sector Supply Chain Directives and the Canada Free Trade Agreement (CFTA). Exceptions, for contracts on which the Member participated occurring during the twelve (12) month reporting period are noted on the attached document with supporting explanations.

In making this attestation, we have exercised care and diligence that would reasonably be expected in these circumstances, including making due inquiries and reviewing results of the self-assessment audits we have completed.

I, Marc Lemaire, Senior Vice President, Strategic Sourcing, I, Dale Thomson, Senior Vice President, National Programs & Sourcing Operations, I, Raechel Griffin, Vice President, Capital, FFE, and Nutrition Services Procurement I, Ally Dhalla, Senior Vice President Pharmacy and Clinical Services & Innovation have the signing authority to make this commitment on behalf of Mohawk Medbuy Corporation.

MOHAWK MEDBUY CORPORATION

A handwritten signature in black ink, appearing to read 'Marc Lemaire'.

Marc Lemaire
Senior Vice President, Strategic
Sourcing
mlemaire@mohawkmedbuy.ca

A handwritten signature in black ink, appearing to read 'Dale Thomson'.

Dale Thomson
Senior Vice President, National
Programs & Sourcing
Operations
dthomson@mohawkmedbuy.ca

A handwritten signature in black ink, appearing to read 'Raechel Griffin'.

Raechel Griffin
Vice President, Capital, FFE
and Nutrition Services
Procurement
rgriffin@mohawkmedbuy.ca

A handwritten signature in black ink, appearing to read 'Ally Dhalla'.

Ally Dhalla
Senior Vice President, Pharmacy and Clinical Services & Innovation
adhalla@mohawkmedbuy.ca



BPS Attestation Report - April 1, 2024 to March 31, 2025

* Reported Spend indicates Member provided data for the Attestation Period. Note that contracts may have started or ended at various points within the Attestation period. Data compiled from October 2023 to September 2024

THP

P = ND Indicates Member participation on contract, however spend data not provided/available.
NP = Not Participating

THRILLUM HEALTH PARTNERS

Code	Contract No.	Contract Name	Supplier Name	Contract Start Date	Current Contract Expiry Date	New Contract Expiry Date (for extended contracts)	Exception Type	Justification Code	SC10245
CAP	2022-P11	CAP-P - HOSPITAL BEDS AND STRETCHERS 2022 - STRYKER	STRYKER CANADA ULC	April 1, 2022	March 31, 2025	December 31, 2026	Appendix A - Limited Tender	D	P=ND
OR	C10220	OR SKIN PREP SYSTEMS 2018 - 3M CANADA	3M HEALTHCARE CANADA CO	June 1, 2018	May 31, 2024	July 31, 2024	Appendix A - Limited Tender	D	\$8,582.94
OR	C10221	OR SKIN PREP SYSTEMS 2018 - BECTON DICKINSON	BECTON DICKINSON CANADA I	June 1, 2018	May 31, 2024	July 31, 2024	Appendix A - Limited Tender	D	\$36,88
OR	C10222	OR SKIN PREP SYSTEMS 2018 - CARDINAL HEALTH	CARDINAL HEALTH CANADA IN	June 1, 2018	May 31, 2024	July 31, 2024	Appendix A - Limited Tender	D	\$2,297.79
OR	C10260	OR HERNIA REPAIR PRODUCTS 2018 - BARD	BARD CANADA INC	November 1, 2018	October 31, 2024	January 31, 2025	Appendix A - Limited Tender	D	\$210,444.65
OR	C10262	OR HERNIA REPAIR PRODUCTS 2018 - MEDTRONIC	MEDTRONIC CANADA -JULC	November 1, 2018	October 31, 2024	January 31, 2025	Appendix A - Limited Tender	D	\$134,045.47
OR	C10263	OR HERNIA REPAIR PRODUCTS 2018 - JJMP	JOHNSON & JOHNSON MEDTE	November 1, 2018	October 31, 2024	January 31, 2025	Appendix A - Limited Tender	D	\$9,346.62
MMCL	C10287	MMCL TRAYS 2018 - CARDINAL	CARDINAL HEALTH CANADA IN	October 1, 2018	September 30, 2024	December 31, 2024	Appendix A - Limited Tender	D	\$22,782.75
INNOV	C10290	INNOV GEKO 2018 PA - TRUDELL MEDICAL MARKETING LTD	TRUDELL MEDICAL MARKETING	August 1, 2028	July 31, 2024	July 31, 2026	Appendix A - Limited Tender	B(i)	P=ND
MMNCL	C10452	MMNCL DRY CELL BATTERIES 2019 - CARDINAL	CARDINAL HEALTH	April 1, 2019	March 31, 2024	November 30, 2024	Appendix A - Limited Tender	D	\$1,220.95
MMNCL	C10500	MMNCL CHEMICALS - DIETARY & LAUNDRY 2019 - BUNZL	BUNZL CANADA INC	September 1, 2019	August 31, 2024	August 30, 2026	Appendix A - Limited Tender	D	\$2,858.08
PH	C10958	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS NEG GSK 2021	GLAXOSMITHKLINE	June 1, 2023	June 1, 2023	January 31, 2024	Appendix A - Limited Tender	B	P=ND
PH	C11175	PH INJECTABLE PHARMACEUTICALS NEG BAX 2021	BAXTER CORPORATION	October 1, 2024	May 31, 2026	January 31, 2024	Appendix A - Limited Tender	A(i)	P=ND
PH	C11216	PH INJECTABLE PHARMACEUTICALS AURO 2021	AURO PHARMA INC.	June 19, 2023	September 30, 2024	September 30, 2024	Appendix A - Limited Tender	B	P=ND
PH	C11223	PH INJECTABLE PHARMACEUTICALS FRK 2021	FRESENIUS KABI CANADA LTD	March 17, 2024	September 30, 2024	September 30, 2024	Appendix A - Limited Tender	B	P=ND
PH	C11230	PH INJECTABLE PHARMACEUTICALS MTP 2021	METHAPHARM	August 25, 2023	September 30, 2024	September 30, 2024	Appendix A - Limited Tender	B	P=ND
PH	C11234	PH INJECTABLE PHARMACEUTICALS OME 2021	OMEGA LABORATORIES LTD.	August 21, 2023	September 30, 2024	September 30, 2024	Appendix A - Limited Tender	B	P=ND
PH	C11307	PH RESERVE INJECTABLE PHARMACEUTICALS JAMP 2021	JAMP PHARMA CORPORATION	May 5, 2023	September 30, 2024	September 30, 2024	Appendix A - Limited Tender	B	P=ND
PH	C11336	PH INJECTABLE MICRONUTRIENTS BAX 2021	BAXTER CORPORATION	October 1, 2024	May 31, 2026	January 31, 2024	Appendix A - Limited Tender	A(i)	P=ND
PH	C11427	PH INJECTABLE PHARMACEUTICALS AGT 2022	LABORATOIRE AQUETTANT CA	April 28, 2023	September 30, 2024	September 30, 2024	Appendix A - Limited Tender	B	P=ND
PH	C11547	PH ONCOLOGY MEDU 2022	MEDUNIK CANADA	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11557	PH PARENTERAL NUTRITION SOLUTIONS + LIPIDS FRK 2022	FRESENIUS KABI CANADA LTD	July 14, 2023	October 31, 2025	September 30, 2025	Appendix A - Limited Tender	B	P=ND
PH	C11579	PH ONCOLOGY APX 2022	APOTEX INC	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11580	PH ONCOLOGY ASP 2022	ASPEN PHARMACARE CANADA	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11582	PH ONCOLOGY BAX 2022	BAXTER CORPORATION	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11585	PH ONCOLOGY SRI 2022	SEARCHLIGHT PHARMA INC.	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11586	PH ONCOLOGY FRK 2022	FRESENIUS KABI CANADA LTD	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11587	PH ONCOLOGY GMP 2022	GENERIC MEDICAL PARTNERS	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11588	PH ONCOLOGY MAR 2022	MARCAN PHARMACEUTICALS I	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11590	PH ONCOLOGY NAT 2022	NATCO PHARMA (CANADA) INC	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11596	PH ONCOLOGY SAV 2022	SANOPLAVENTIS CANADA INC.	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11597	PH ONCOLOGY TAR 2022	TARO PHARMACEUTICALS INC	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11599	PH ONCOLOGY VLO 2022	VALO PHARMA	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11623	PH RESERVE ONCOLOGY APX 2022	APOTEX INC	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11634	PH RESERVE ONCOLOGY STM 2022	STERIMAX	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11643	PH RESERVE ONCOLOGY PPI 2022	PIZER CANADA ULC	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
PH	C11648	PH RESERVE ONCOLOGY JAMP 2022	JAMP PHARMA CORPORATION	January 1, 2025	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B(i)	P=ND
OR	C11693	OR SPINAL SYSTEMS 2023 - JJMP	JOHNSON & JOHNSON MEDTE	January 1, 2023	December 31, 2024	June 30, 2025	Appendix A - Limited Tender	D	\$2,381,179.22
OR	C11694	OR MPSC SPINAL SYSTEMS 2023 - STRYKER	STRYKER CANADA ULC	January 1, 2023	December 31, 2024	June 30, 2025	Appendix A - Limited Tender	D	\$4,676,131.94
PH	C11715	PH PHARMACY SUPPLIES PMS 2022	PHARMASYS SYSTEMS INC.	November 1, 2023	November 30, 2025	November 30, 2025	Appendix A - Limited Tender	B	\$9,791.13
PH	C11881	PH PREFILLED LOCK FLUSH SYRINGES + DEVICES BD 2023	BECTON DICKINSON CANADA I	May 1, 2023	April 30, 2026	December 31, 2028	Appendix A - Limited Tender	B(i)	\$25,200.00
PH	C11871	PH ORAL SOLID PHARMACEUTICALS APX 2023	APOTEX INC	July 1, 2023	March 31, 2027	March 31, 2027	Appendix A - Limited Tender	B	P=ND
PH	C11899	PH ORAL SOLID PHARMACEUTICALS TEVA 2023	TEVA CANADA LIMITED INC	July 1, 2023	March 31, 2027	March 31, 2027	Appendix A - Limited Tender	B	P=ND
PH	C12122	PH BIOSIMILAR ONCOLOGY NCCNEG ORG 2023	ORGANON CANADA INC.	July 1, 2023	September 30, 2024	September 30, 2024	Appendix A - Limited Tender	B	P=ND
PH	C12158	PH ONCOLOGY EBSI 2023	EBSI LIMITED	February 1, 2024	September 30, 2025	September 30, 2025	Appendix A - Limited Tender	B	P=ND
PH	C12170	PH INJECTABLE PHARMACEUTICALS JUL 2023	JUNIPER CANADA LTD.	September 26, 2023	September 30, 2024	September 30, 2024	Appendix A - Limited Tender	B	P=ND
PH	C12283	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS BALC 2024	BAUSCH + LOMB CORPORATE	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	\$1,255.20
PH	C12293	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS KEN 2024	KENVUE CANADA LTD.	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	B	P=ND
PH	C12300	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS NOR 2024	NORWELL CONSUMER HEALTH	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12301	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS NVR 2024	NOVARTIS PHARMACEUTICALS	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12306	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS PDL 2024	PALADIN PHARMA INC.	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12317	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS TEVA 2024	TEVA CANADA LIMITED INC	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12318	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS VLO 2024	VALO PHARMA	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12407	PH RESERVE NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS AURO	AURO PHARMA INC.	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12408	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS STOM 2024	STOM PHARMA INC.	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12415	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS HTH 2024	HEALTHMARK SERVICES	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12424	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS SPI 2024	SEARCHLIGHT PHARMA INC.	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12425	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS ATL 2024	ATLAS LABORATOIRE INC.	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	\$3,452.31
PH	C12426	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS SFR 2024	SEAFORD PHARMACEUTICALS	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12436	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS LEO 2024	LEO PHARMA INC	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12442	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS JUL 2024	JUNIPER CANADA LTD.	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12475	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS ESS 2023	ESSENTIAL PHARMA	December 15, 2023	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12478	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS COVS 2024	COVS PHARMA CANADA LTD.	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND
PH	C12483	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS AAP 2024	AA PHARMA INC.	February 1, 2024	January 31, 2027	January 31, 2027	Appendix A - Limited Tender	A(i) & B	P=ND

PH	C12520	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS ALC 2024	ALCON CANADA INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(8) & B	P&ND
PH	C12523	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS KNI 2024	KNIGHT THERAPEUTICS INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(8) & B	P&ND
PH	C12541	PH ERYTHROPOIESIS STIMULATING AGENTS NCCNEG AMG 2024	AMGEN CANADA INC.	July 1, 2024	June 30, 2027		Appendix A - Limited Tender	B	P&ND
PH	C12542	PH ERYTHROPOIESIS STIMULATING AGENTS NCCNEG JAN 2024	JANSSEN INC.	July 1, 2024	June 30, 2027		Appendix A - Limited Tender	B	P&ND
PH	C12690	PH INJECTABLE PHARMACEUTICALS BAY 2024 EXCLUSIVE	BAYER INC.	July 1, 2024	September 30, 2024		Appendix A - Limited Tender	C(0)	P&ND
MILR	C12703	MILR RADIOPHARMACEUTICALS 2024 - NUCM - PA	NUCM RADIOPHARMA INC.	April 1, 2024	September 30, 2024	December 31, 2024	Appendix A - Limited Tender	D	P&ND
PH	C12733	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS NCCNEG ON HI	HOFFMANN-LA ROCHE LIMITED	February 20, 2024	January 31, 2027		Appendix A - Limited Tender	A(8) & B	P&ND
OR	C12765	OR ENDOSCOPIC VESSEL HARVESTING 2024 - PA - GETINGE	GETINGE CANADA LTD.	June 1, 2024	May 31, 2026		Appendix A - Limited Tender	D	P&ND
PH	C12780	PH ONCOLOGY EPI 2024	EUGIA PHARMA INC.	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(0)	P&ND
PH	C12943	PH BIOLOGIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS SDZ 2024	SANDOZ CANADA INC	October 1, 2024	May 31, 2027		Appendix A - Limited Tender	A(0)	P&ND
PH	C12951	PH INJECTABLE PHARMACEUTICALS ASP 2024	ASPEN PHARMACEUTICALS CANADA	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C12953	PH INJECTABLE PHARMACEUTICALS AVIR 2024	AVIR PHARMA INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C12959	PH INJECTABLE PHARMACEUTICALS HCL 2024	HIKMA CANADA LTD.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C12967	PH INJECTABLE PHARMACEUTICALS MTP 2024	MITHAPHARM	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C12972	PH INJECTABLE PHARMACEUTICALS PHH 2024	PFIZER CANADA ULC	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C12979	PH INJECTABLE PHARMACEUTICALS STM 2024	STERIMAX	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13032	PH SEVOFLURANE INHALATION ANESTHETIC ABB 2024	ABBVIE CORPORATION	October 1, 2024	September 30, 2026		Appendix A - Limited Tender	A5 (v)	P&ND
PH	C13033	PH SEVOFLURANE INHALATION ANESTHETIC BAX 2024	BAXTER CORPORATION	October 1, 2024	September 30, 2026		Appendix A - Limited Tender	A5 (v)	P&ND
PH	C13034	PH SEVOFLURANE INHALATION ANESTHETIC CHS 2024	CANADIAN HOSPITAL SPECIALTIES LTD.	October 1, 2024	September 30, 2026		Appendix A - Limited Tender	A5 (v)	P&ND
PH	C13054	PH INJECTABLE PHARMACEUTICALS GMP 2024	GENERIC MEDICAL PARTNERS	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13164	PH RESERVE INJECTABLE PHARMACEUTICALS MAR 2024	MARCAN PHARMACEUTICALS	January 1, 2025	May 31, 2028		Appendix A - Limited Tender	B(0)	P&ND
PH	C13176	PH RESERVE INJECTABLE PHARMACEUTICALS JAMP 2024	JAMP PHARMA CORPORATION	January 1, 2025	May 31, 2028		Appendix A - Limited Tender	B(0)	P&ND
PH	C13178	PH ONCOLOGY PHARMACEUTICALS AND 2024	ANDONE PHARMACEUTICALS	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(0)	P&ND
OR	C13179	OR INTRA AORTIC BALLOON PUMPS AND ACCESSORIES 2024 - TELEFLEX	TELEFLEX MEDICAL CANADA INC	October 1, 2024	July 31, 2027		Appendix A - Limited Tender	B(v)	P&ND
PH	C13184	PH RESERVE INJECTABLE PHARMACEUTICALS ASP 2024	ASPEN PHARMACEUTICALS CANADA	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13212	PH RESERVE INJECTABLE PHARMACEUTICALS RDY 2024	DR. REDDY'S LABORATORIES	January 1, 2025	May 31, 2028		Appendix A - Limited Tender	B(0)	P&ND
PH	C13341	PH ONCOLOGY SS PH 2024	PFIZER CANADA ULC	October 1, 2024	September 30, 2025		Appendix A - Limited Tender	B(0)	P&ND
PH	C13463	PH INJECTABLE PHARMACEUTICALS ORG 2024	ORGANON CANADA INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13464	PH INJECTABLE PHARMACEUTICALS SFR 2024	SEAFORD PHARMACEUTICALS	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13542	PH INJECTABLE PHARMACEUTICALS BBC 2024	B. BRAUN OF CANADA LTD	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13615	PH INJECTABLE PHARMACEUTICALS SUM 2024	SUMITOMO PHARMA CANADA INC	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13689	PH INJECTABLE PHARMACEUTICALS ALC 2024	ALCON CANADA INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13690	PH INJECTABLE PHARMACEUTICALS NNO 2024	NOVO NORDISK CANADA INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13691	PH INJECTABLE PHARMACEUTICALS XED 2024	XEDION PHARMACEUTICALS	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13803	PH INJECTABLE PHARMACEUTICALS KNI 2024	KNIGHT THERAPEUTICS INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13804	PH INJECTABLE PHARMACEUTICALS PDL 2024	PALADIN PHARMA INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13805	PH INJECTABLE PHARMACEUTICALS HLR 2024	HOFFMANN-LA ROCHE LIMITED	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C13911	PH BIOLOGIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS LEO 2025	LEO PHARMA INC	October 1, 2024	May 31, 2027		Appendix A - Limited Tender	A(0)	P&ND
PH	C14057	PH INJECTABLE PHARMACEUTICALS NCCNEG FRK 2024	FRESENIUS KABI CANADA LTD.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C14127	PH INJECTABLE PHARMACEUTICALS LEO 2025	LEO PHARMA INC	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
PH	C14202	PH INJECTABLE PHARMACEUTICALS LBI 2025	LEADMANT BIOSCIENCES INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(0)	P&ND
OR	C8672	OR PELVIC SUPPORT PRODUCTS 2016 - JUMP	J&J	October 1, 2015	May 31, 2024	May 31, 2025	Appendix A - Limited Tender	D	\$13,643.50
OR	C8909	OR TRAUMA AND BONE FIXATION PRODUCTS - SPINAL SYSTEMS 2016 - MEDT	MEDTRONIC CANADA-ULC.	April 1, 2016	December 31, 2024	June 30, 2025	Appendix A - Limited Tender	D	\$63,809.67
MMNCL	C8955	MMNCL STERILIZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016 - ADVANCED STERILIZATION PR	SOUTHMEDIC	May 1, 2016	June 30, 2025	June 30, 2025	Appendix A - Limited Tender	D	\$6,890.01
MMNCL	C9109	MMNCL DECONTAMINATION PRODUCTS 2017 - STERIS	STERIS	January 1, 2017	May 31, 2024	March 31, 2025	Appendix A - Limited Tender	D	\$10,618.48
MMNCL	C9113	MMNCL DECONTAMINATION PRODUCTS 2017 - SOUTHMEDIC	SOUTHMEDIC	February 1, 2017	May 31, 2024	March 31, 2025	Appendix A - Limited Tender	D	\$349.17
MILR	C0955874	MILR BLOOD BANK AUTOMATION SYSTEM 2018 - ORTHO CLINICAL DIAGNOSTICS	QUIDELCORTHO CANADA CORP	August 31, 2018	December 15, 2024	December 15, 2029	Appendix A - Limited Tender	B(3)	\$3,196.02
MILR	MMC-1807A	MILR RADIOPHARMACEUTICALS 2018 - LANTHEUS	LANTHEUS MICHIGAN INC.	April 1, 2018	March 31, 2024	December 31, 2024	Appendix A - Limited Tender	D	P&ND
MILR	MMC-1807B	MILR RADIOPHARMACEUTICALS 2018 - GE	GE HEALTHCARE TECHNOLOGIES	September 10, 2018	September 9, 2024	December 31, 2024	Appendix A - Limited Tender	D	P&ND
MILR	MMC-1807C	MILR RADIOPHARMACEUTICALS 2018 - ISOLOGIC	ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS	April 1, 2018	March 31, 2024	December 31, 2024	Appendix A - Limited Tender	D	P&ND
MILR	MMC-1807D	MILR RADIOPHARMACEUTICALS 2018 - CURIUM	CURIUM	April 1, 2018	March 31, 2024	December 31, 2024	Appendix A - Limited Tender	D	\$5,175.66
MILR	MSS-1807B	MILR RADIOPHARMACEUTICALS 2018 - JUB DRAX	JUBILANT DRAXIMAGE INC.	April 1, 2018	March 31, 2024	December 31, 2024	Appendix A - Limited Tender	D	\$15,313.60
MMNCL	NSC 19-05	NSC MORD STERILE CONTAINERS 2021 - TRUDELL	TRUDELL HEALTHCARE SOLUTIONS	March 1, 2021	February 28, 2025	September 30, 2025	Appendix A - Limited Tender	D	\$64,927.06

Report Definition and Reference Tables

* Reported Spend indicates Member provider data for the Attestation Period. Note that contracts may have started or ended at various points within the Attestation period. Data compiled from October 2023 to September 2024

P=ND Indicates Members Participation on Contract, however spend data not provided/available

NP=Not Participating

Appendix A – Limited Tendering (Article 513)

Limited Tendering: means a procurement method whereby the procuring entity contacts a supplier or suppliers of its choice. In accordance with the CFTA Chapter 5 (Government Procurement), an organization may use Limited Tendering in the following circumstances, provided that it does not use this provision for the purpose of avoiding competition among suppliers or in a manner that discriminates against suppliers or any other Party or protects its own suppliers.

- ☐ (a) if:
 - ☐ (i) no tenders were submitted or no suppliers requested participation;
 - ☐ (ii) no tenders that conform to the essential requirements of the tender documentation were submitted;
 - ☐ (iii) no suppliers satisfied the conditions for participation; or
 - ☐ (iv) the submitted tenders were collusive provided that the requirements of the tender documentation are not substantially modified;
- ☐ (b) if the goods or services can be supplied only by a particular supplier and no reasonable alternative or substitute goods or services exist for any of the following reasons:
 - ☐ (i) the requirement is for a work of art;
 - ☐ (ii) the protection of patents, copyrights, or other exclusive rights;
 - ☐ (iii) due to an absence of competition for technical reasons;
 - ☐ (iv) the supply of goods or services is controlled by a supplier that is a statutory monopoly;
 - ☐ (v) to ensure compatibility with existing goods, or to maintain specialized goods that must be maintained by the manufacturer of those goods or its representative;
 - ☐ (vi) work is to be performed on property by a contractor according to provisions of a warranty or guarantee held in respect of the property or the original work;
 - ☐ (vii) work is to be performed on a leased building or related property, or portions thereof, that may be performed only by the lessor; or
 - ☐ (viii) the procurement is for subscriptions to newspapers, magazines, or other periodicals;
- ☐ (c) for additional deliveries by the original supplier of goods or services that were not included in the initial procurement, if a change of supplier for such additional goods or services:
 - ☐ (i) cannot be made for economic or technical reasons such as requirements of interchangeability or interoperability with existing equipment, software, services, or installations procured under the initial procurement; and
 - ☐ (ii) would cause significant inconvenience or substantial duplication of costs for the procuring entity;
- ☐ (d) if strictly necessary, and for reasons of urgency brought about by events unforeseeable by the procuring entity, the goods or services could not be obtained in time using open tendering;
- ☐ (e) for goods purchased on a commodity market;
- ☐ (f) if a procuring entity procures a prototype or a first good or service that is developed in the course of, and for, a particular contract for research, experiment, study, or original development. Original development of a first good or service may include limited production or supply in order to incorporate the results of field testing and to demonstrate that the good or service is suitable for production or supply in quantity to acceptable quality standards, but does not include quantity production or supply to establish commercial viability or to recover research and development costs;
- ☐ (g) for purchases made under exceptionally advantageous conditions that only arise in the very short term in the case of unusual disposals such as those arising from liquidation, receivership, or bankruptcy, but not for routine purchases from regular suppliers;
- ☐ (h) if a contract is awarded to a winner of a design contest provided that:
 - ☐ (i) the contest has been organized in a manner that is consistent with the principles of this Chapter, in particular relating to the publication of a tender notice; and
 - ☐ (ii) the participants are judged by an independent jury with a view to a design contract being awarded to a winner; or
- ☐ (i) if goods or consulting services regarding matters of a confidential or privileged nature are to be purchased and the disclosure of those matters through an open tendering process could reasonably be expected to compromise government confidentiality, result in the waiver of privilege, cause economic disruption, or otherwise be contrary to the public interest.

Appendix B – Non-Application (Article 504)

Non-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to:

- ☐ (a) public employment contracts;
- ☐ (b) non-legally binding agreements;
- ☐ (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives;
- ☐ (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the agreement includes rules for awarding contracts that differ from the obligations of this Chapter;
- ☐ (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon;
- ☐ (f) measures necessary to protect intellectual property, provided that the measures are not applied in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the same conditions prevail or are a disguised restriction on trade;
- ☐ (g) procurement or acquisition of:
 - ☐ (i) fiscal agency or depository services;
 - ☐ (ii) liquidation and management services for regulated financial institutions; or
 - ☐ (iii) services related to the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities;
- ☐ (h) procurement of:
 - ☐ (i) financial services respecting the management of government financial assets and liabilities (i.e., treasury operations), including ancillary advisory and information services, whether or not delivered by a financial institution;
 - ☐ (ii) health services or social services;
 - ☐ (iii) services that may, under applicable law, only be provided by licensed lawyers or notaries; or
 - ☐ (iv) services of expert witnesses or factual witnesses used in court or legal proceedings; or
- ☐ (i) procurement of goods or services:
 - ☐ (i) financed primarily from donations that require the procurement to be conducted in a manner inconsistent with this Chapter;
 - ☐ (ii) by a procuring entity on behalf of an entity not covered by this Chapter;
 - ☐ (iii) between enterprises that are controlled by or affiliated with the same enterprise, or between one government body or enterprise and another government body or enterprise;
 - ☐ (iv) by non-governmental bodies that exercise governmental authority delegated to them;
 - ☐ (v) from philanthropic institutions, non-profit organizations, prison labour, or natural persons with disabilities;
 - ☐ (vi) under a commercial agreement between a procuring entity which operates sporting or convention facilities and an entity not covered by this Chapter that contains provisions inconsistent with this Chapter;
 - ☐ (vii) conducted for the specific purpose of providing international assistance, including development aid, provided that the procuring entity does not discriminate on the basis of origin or location within Canada of goods, services, or suppliers; or
 - ☐ (viii) conducted:
 - ☐ (A) under the particular procedure or condition of an international agreement relating to the stationing of troops or relating to the joint implementation by the signatory countries of a project; or
 - ☐ (B) under the particular procedure or condition of an international organization, or funded by international grants, loans, or other assistance, if the procedure or condition would be inconsistent with this Chapter,

Appendix C – US Vendor

- ☐ (a) U.S. business was the only viable source and the procurement could not be delayed



April 29, 2025

Tony DiEmanuele
President & CEO
Mohawk Medbuy
100 – 1107 Clay Avenue
Burlington, ON L7L 0A1

Dear Tony,

Re: Ontario Ministry of Finance Broader Public Sector (BPS) Procurement Directive

We have reviewed our contracting processes and documents and can attest to HealthPRO's compliance to the Ontario Broader Public Sector Act Procurement Directive for the fiscal year 2024/25.

There are no extensions to report for our contracts for the 2024/25 fiscal year.

If you require additional information, please contact Ms. Kendra Frey, Vice President, Strategic Sourcing and Innovative Solutions (289-805-7920) or Mr. Jeff Sparks, Vice President, Member Success (905-568-7284).

Sincerely,

A handwritten signature in black ink, appearing to read "CDonaldson", is written over a light blue horizontal line.

Christine Donaldson
President & CEO
HealthPRO Canada

TO: Trillium Health Partners, Toronto

FROM: Nils Clausen
Chief Executive Officer (CEO)
CMEPP - Canadian Medical Equipment Protection Plan

Date: May 1, 2025

Re: Canadian Medical Equipment Protection Plan (the "CMEPP")
Re: Compliance with Broader Public Sector Procurement Directive (the "Directive")

Organizations that participate in group purchasing activities through buying groups and other procurement services organizations must ensure that the activities of these entities are carried out in a manner consistent with the Directive.

For the fiscal year 2024/2025, acting in accordance with the instructions and information received from your hospital/organization, CMEPP conducted its procurement activities on your behalf in a manner that is compliant with the Directive.

In stating so, CMEPP exercised care and diligence that would be reasonably expected of a CEO in these circumstances, including making due inquiries of CMEPP personnel that have knowledge of these matters.

Yours truly,



Nils Clausen
CEO

Linda Pichikian
Trillium Health Partners

May 2, 2025

Dear Linda,

The enclosed letter serves as an attestation that OECM conducts all sourcing initiatives in compliance with the Broader Public Sector (BPS) Procurement Directive as well as other trade agreements.

OECM, and the customers we serve follow the BPS Procurement Directive. The directive sets out rules for designated BPS entities on the purchase of goods and services using public funds.

The purpose of the directive is:

- To ensure that goods and services, including construction, consulting services, and information technology are acquired by BPS entities through a process that is open, fair, and transparent;
- To outline responsibilities of BPS entities throughout each stage of the procurement process; and,
- To ensure that all BPS entities in Ontario are consistently managing their procurement processes.

In addition, OECM's sourcing initiatives are undertaken within the scope of Chapter 5 of the Canadian Free Trade Agreement ("CFTA"), Chapter 19 of the Comprehensive Economic and Trade Agreement ("CETA"), and within the scope of the Trade and Cooperation Agreement between Quebec and Ontario.

I also enclose a link to the Ontario Tender's Portal (OTP) website where all of OECM's RFPs are posted: <https://ontariotenders.bravosolution.com/esop/nac-host/public/home.html>

Should you have any questions, or require further information, please don't hesitate to contact our Customer Support Team at customersupport@oecm.ca or 1-844-OECM-900 (1-844-632-6900).

Sincerely,



Perry Arzumanian
Director, Strategic Sourcing

List of Consultants

Name of Hospital: Trillium Health Partners

Reporting Period: April 1 2024 to March 31 2025.

No.	Consulting Firm (Name)	Name & Title of Consulting Contract	Contract Terms (Original plus renewals / amendments)	Procurement Value (Originals Plus renewals / amendments and TOTAL PAID)	Consulting Selection Process (Invitational competitive, open competitive, or non-competitive)	Any modifications to the agreement (Yes/No)? If "yes" - please indicated whether the procurement documents allowed for this (Yes/No)? If modification not permitted, ensure modification is captured on the BPS Non Compliance and Exceptions Reporting Form
1	Santis; Counsel Public Affairs; Rivet (2542060 Ontario Inc.); StrategyCorp, Curious Public Content and Insights	Crisis & Corporate Communications Services (Multi-award)	November 1, 2019 to October 31, 2024	Total Procurement Value: \$462,143 plus tax (includes consulting & non-consulting)	Open competitive- Second Stage invitation & Non competitive	Yes, amended to exercise the option years. Amendment as second stage non-competitive to add Anti-Black racism to Curious Public starting Aug.8, 2022.
				Total Paid to Date: \$257,394		
2	Counsel Public Affairs Inc., Curious Public Content and Insights, Inc., KAPOW Communications Inc, Pineapple Media, RC Design Inc., Santis Health, Sussex Strategy Group	Communication Services	December 9, 2024 to December 8, 2027 (or when proejct is over)	Total Procurment Value: \$610,000 plus tax (mainly non-consulting)	Open competitive, Second stage procurement	No modifications
				Total paid to date: \$16,440		
3	LOH Architects Associates Inc.	Retail Strategy - Broader Redevelopment Project	December 1, 2018 to December 31, 2025	Total Procurement Value: \$330,550 plus tax (includes consulting and non-consulting)	Open competitive and non-competitive	Amendment #1 was done to include additional scope of \$75k
				Total Paid to Date: \$224,553		
4	KPMG Corporate Finance Inc.	Advisory Assistance for Financing Requirements	June 11, 2018 to June 10, 2026	Total Procurement Value: \$1,924,675 plus tax (includes consulting and non-consulting)	Open competitive	With amendments term was increased from 2023 to 2026
				Total Paid to Date: \$431,043		
5	Cushman & Wakefield ULC, Brokerage	Commercial Real Estate Advisory Services	November 1, 2018 to October 31, 2025	Total Procurement Value: \$1,009,700 plus tax (includes consulting and non-consulting)	Open competitive	No modifications
				Total Paid to Date: \$533,137		
6	Deloitte Inc.	THP Local Share Plan Consultant	December 11, 2020 to December 31, 2025	Total Procurement Value:\$469,000 plus tax (includes consulting and non-consulting)	Open competitive	No modifications
				Total Paid to Date: \$284,272		
7	Selectpath Benefits and Financial Inc.	HR Benefits Consulting Services	November 1, 2021 to October 31, 2026	Total Procurement Value:\$278,357 plus tax (includes consulting and non-consulting)	Open competitive	No modifications
				Total Paid to Date: \$243,121		

No.	Consulting Firm (Name)	Name & Title of Consulting Contract	Contract Terms (Original plus renewals / amendments)	Procurement Value (Originals Plus renewals / amendments and TOTAL PAID)	Consulting Selection Process (Invitational competitive, open competitive, or non-competitive)	Any modifications to the agreement (Yes/No)? If "yes" - please indicated whether the procurement documents allowed for this (Yes/No)? If modification not permitted, ensure modification is captured on the BPS Non Compliance and Exceptions Reporting Form
8	Janice Stein Consulting Services Ltd.	Advisory Services related to Departmental Review	November 23rd, 2023 to July 31st, 2024	Total Procurement Value: 7,500 plus tax	Non-competitive	No modifications
				Total Paid to Date: \$Nil		
9	ML Consulting	Pay Equity Services	September 1, 2022 to August 31, 2027	Total Procurement Value:\$99,938 plus tax (includes consulting and non-consulting)	Invitational competitive	No modifications
				Total Paid to Date: \$12,837		
10	Ernst & Young Global Limited	Financial Systems Advisory	August 15, 2022 to July 31, 2024	Total Procurement Value:\$125,000 plus tax	Open competitive	No modifications
				Total Paid to Date: \$124,099		
11	Preyra Solutions Group	Capacity Planning and Peer Benchmarking	January 1, 2024to December 31, 2030	Total Procurement Value: \$393,750 plus tax (includes consulting & non-consulting)	Open competitive	No modifications
				Total Paid to Date: \$13,272		
12	Deloitte Inc.	Digital Analytics and Data Governance Roadmap Development	September 6, 2023 to September 5, 2026	Total Procurement Value: \$180,000 plus tax (includes consulting & non-consulting)	Open competitive	No modifications
				Total Paid to date: \$60,000		
13	Coach Chihab Group Inc	Engagement of Physician Leaders and Division Members	December 15th, 2024 to December 14th, 2026	Total Procurement Value: \$38,000 plus tax	Non competitive	No modifications
				Total Paid to Date: \$Nil		
14	Strategy Corp Inc.	Communication Services	November 1st, 2025 to December 31st, 2025	Total Procurement Value: \$50,000	Non competitive	No modifications
				Total Paid to Date: \$14,344		